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CASE REPORT
Bartter’s Syndrome with Type 2 Diabetes Mellitus
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We report a rare case of Bartter’s syndrome in a 35-year-old woman with type 2 diabetes mellitus. The patient presented
with leg weakness, fatigue, polyuria and polydipsia. Hypokalemia, metabolic alkalosis, and high renin and aldosterone
concentrations were present, but the patient was normotensive. Gitelman’s syndrome was excluded because of the presence
of hypercalciuria, secondary hyperparathyroidism and bilateral nephrocalcinosis. The patient’s condition improved upon
administration of a prostaglandin synthetase inhibitor (acemetacin), oral potassium chloride and potassium-sparing
diuretics. Five months later, the patient discontinued acemetacin because of epigastric discomfort; at the same time, severe
hypokalemia and hyperglycemia developed. Glucagon stimulation and water deprivation tests were performed. Type 2
diabetes mellitus with nephrogenic diabetes insipidus was diagnosed. To avoid further gastrointestinal complications,
the patient was treated with celecoxib, a selective cyclooxygenase 2 inhibitor. This case serves as a reminder that Bartter’s
syndrome is associated with various metabolic derangements including nephrogenic diabetes insipidus, nephrocalcinosis
and diabetes mellitus. When treating Bartter’s syndrome, it is also prudent to remember that the long-term use of nonsteroidal
anti-inflammatory drugs and potassium-sparing diuretics may result in serious adverse reactions. [J Chin Med Assoc
2009;72(2):88–90]
Key Words: Bartter, diabetes mellitus, hypokalemia, syndrome
*Correspondence to: Dr Siu-Pak Lee, Section of Neurology, Department of Internal Medicine, Far
Eastern Memorial Hospital, 21, Section 2, Nan-Ya South Road, Panchiao, Taipei 220, Taiwan, R.O.C.
E-mail: siupakmd@ms1.hinet.net ● Received: April 14, 2008 ● Accepted: September 9, 2008
Introduction
Bartter’s syndrome, a constellation of renal tubular
disturbances, is characterized by hypokalemia, meta-
bolic alkalosis with hyperreninemia, and hyperaldo-
steronism.1 Clinically, patients may present with fatigue,
polyuria and polydipsia. These signs and symptoms
overlap with those manifested by patients with diabetes
mellitus. Furthermore, hypokalemia may serve to pro-
mote glucose intolerance.2 A MEDLINE search using
“Bartter’s syndrome” and “diabetes mellitus” as key
words revealed 1 report of a case of Bartter’s syndrome
concurrent with type 1 diabetes mellitus over the past
40 years.3 The present report describes a rare case of
Bartter’s syndrome with type 2 diabetes mellitus and
the various treatment modalities, including a selective
cyclooxygenase 2 (COX-2) inhibitor, utilized. The rela-
tionship between Bartter’s syndrome and diabetes
mellitus is explored.
Case Report
A 35-year-old woman with bilateral leg weakness,
fatigue, polyuria and polydipsia consulted the outpa-
tient clinic of Far Eastern Memorial Hospital. Rou-
tine blood tests revealed a serum potassium level of
2.2 mmol/L. Her fasting blood glucose was 108 mg/
dL, serum calcium was 9.6 mg/dL, serum sodium was
134 mmol/L, and serum chloride was 87 mmol/L.
Physical examination was unremarkable. She was nor-
motensive with normal hearing ability. Her blood pres-
sure was 102/70 mmHg, body weight was 58 kg, and
height was 162cm. She was not on any medications, in-
cluding diuretics. She denied family history of hypoka-
lemia, diabetes mellitus or renal stone.
Further work-up was performed to evaluate the hy-
pokalemia (Table 1). Venous blood gas measurements
revealed metabolic alkalosis. Her urinary potassium,
calcium and chloride excretion rates were increased.
There was hyperreninemic hyperaldosteronism. Serum
creatinine, calcium, phosphate and magnesium levels
were normal. Intact parathyroid hormone was 196 pg/
dL (normal, 12–65 pg/dL). A parathyroid scan with
Tc-99m MIBI injection showed bilateral parathyroid
hyperplasia, but bone mineral density was normal.
Renal ultrasound revealed bilateral nephrocalcinosis.
A diagnosis of Bartter’s syndrome was made.
A prostaglandin synthetase inhibitor (acemetacin,
60mg), oral potassium chloride (600mg), and spirono-
lactone (25 mg) were administered 3 times daily. One
week following initiation of this regimen, polyuria
and polydipsia were relieved and the potassium value
had increased to 3.3 mmol/L. Four months later, the
patient discontinued acemetacin because of epigastric
discomfort.
Five months later, however, she visited the emer-
gency room due to epigastric pain, vomiting and gen-
eral weakness. Her potassium was 1.9mmol/L, random
blood glucose was 383 mg/dL, and hemoglobin A1c
(HbA1c) was 11.8%. Arterial blood gas measurements
revealed metabolic alkalosis; ketones were not present
in serum or urine. Upon admission for further manage-
ment, fluid and potassium replacements were adminis-
tered. The patient’s blood glucose and potassium values
improved. A glucagon stimulation test was performed.
Fasting C-peptide level was 6.5 ng/mL (normal, 1.00–
7.60 ng/mL); 6 minutes after glucagon injection, this
value rose to 8.2 ng/mL. Although blood glucose
values stabilized, polyuria remained. The patient then
underwent a water deprivation test. After 12 hours of
water deprivation, serum osmolality was 298mOsm/
kg and urine osmolality was 175 mOsm/kg. One hour
after injection of vasopressin, urine osmolality was
198 mOsm/kg. These findings supported the presence
of nephrogenic diabetes insipidus. Glimepiride (2 mg)
and metformin (500 mg) were administered twice daily
to control blood glucose. To decrease the possibility of
epigastric pain while controlling potassium, the selec-
tive COX-2 inhibitor celecoxib (200 mg once daily)
was substituted for acemetacin. The patient’s condition
stabilized, with potassium values maintained at approx-
imately 3 mmol/L and HbA1c values maintained at
approximately 7%.
Discussion
In Bartter’s syndrome, a transporter defect at the thick
ascending limb of Henle’s loop disrupts sodium and
chloride reabsorption.4 Decreased sodium reabsorp-
tion also reduces the electrical gradient driving calcium
and magnesium reabsorption, resulting in hypomag-
nesemia and hypercalciuria.4 The resultant hypercalci-
uria favors formation of renal stones and secondary
hyperparathyroidism.5 An increase in circulating para-
thyroid hormone concentrations can promote bone 
resorption such that osteopenia or osteoporosis may de-
velop. However, our patient with high parathyroid hor-
mone concentrations exhibited normal bone mineral
density of the lumbar spine as detected by dual-energy
X-ray absorptiometry. The reason why our patient main-
tained a normal lumbar spine bone mineral density is
probably due to the fact that the spine is rich in trabec-
ular bone. It has been reported that the usual pattern
in hyperparathyroidism is lower bone mineral density
at sites rich in cortical rather than trabecular bone
(forearm > hip > spine).6
The hypokalemia of Bartter’s syndrome can be
highly refractory to pharmacotherapy. Although potas-
sium administered orally at high doses usually does not
suffice as single therapy, addition of potassium-sparing
diuretics may prove helpful. Reduction of prostaglandins
with indomethacin has proven efficacious in mainte-
nance of potassium values.3 Long-term use of this cyclo-
oxygenase inhibitor in subjects with Bartter’s syndrome,
however, is associated with gastrointestinal bleeding
and renal failure.1 The angiotensin-converting enzyme
inhibitors (ACEIs) enalapril and captopril have also been
used to treat Bartter syndrome.7 However, hypotension
was observed in some type 2 diabetic patients during
the first few days of treatment with these agents.8 Pro-
pranolol has been used successfully in some patients
to alleviate hypokalemia through reductions in renin
and aldosterone.9 It should be noted, however, that
ACEIs and propranolol were not found to be benefi-
cial in the treatment of Bartter’s syndrome in other
studies.4
There was probably a delay in the diagnosis of glu-
cose intolerance in our patient because her fasting
blood glucose was 108 mg/dL during her initial visit.
The disability of urinary concentration in Bartter’s syn-
drome aggravated the patient’s hyperglycemia. Patients
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Table 1. Laboratory workups to evaluate hypokalemia
Results Normal values
Urine potassium (mmol/d) 53.2 <25
Urine chloride (mmol/d) 38.1 <20
Urine calcium (mg/kg/d) 7.47 <4
Renin (pg/mL) 142 1.80–59.40
Aldosterone (pg/mL) 792 38–313
Serum pH 7.475 7.30–7.45
PCO2 (mmHg) 47.9 32–46
HCO3– (mmol/L) 34.5 21–29
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with Bartter’s syndrome display elevated insulin con-
centrations, with hyperplasia of the islets of Langerhans
as noted at autopsy.3 However, insulin secretion is de-
creased in hypokalemia,2,3 and potassium infusions
improve glucose tolerance by increasing insulin and
proinsulin concentrations.10 We should be aware of the
fact that Bartter’s syndrome is associated with various
metabolic and electrolyte derangements. Treatment can
be complicated, and the long-term use of NSAIDs and
potassium-sparing diuretics in this disorder remains a
challenging issue for clinicians.
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